Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

Incyte secured an interim injunction in India against Melody Healthcare regarding its ruxolitinib patent, just 11 weeks before the patent's expiration. The Delhi High Court ruled in favor of interim protection due to the patent's remaining validity and lack of competing commercial launch. According to the court, this ruling highlights the availability of interim protection against threatened infringement before a rival's commercial launch.

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.

Incyte (INCY) reported Q3 revenue of $1.56B, up 14% YoY, with net sales also rising 14% to $1.32B. All products grew, led by Jakafi and OPZELURA. The company raised full-year sales guidance to $5.21B-$5.3B. Management highlighted a larger late-stage pipeline but noted risks including higher expenses and pricing pressure on Jakafi.

Incyte (INCY) and Genmab (GMAB) will jointly fund a Phase 1/2 trial combining Incyte's KRAS G12D inhibitor (INCB161734) and Genmab's bispecific antibody (petosemtamab) with chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The trial aims to evaluate the combination's safety and efficacy, targeting a subtype with limited treatment options.

Oppenheimer upgraded Incyte to Outperform, citing growth prospects beyond Jakafi's 2029 exclusivity loss. The firm set a $144 price target, 23% above Incyte's Oct. 29 closing price.

Incyte Corporation (INCY) reported Q3 2026 revenue of $1.56 billion, up 14% YoY, beating estimates. Full-year guidance was raised to $5.26 billion, though still below analyst expectations. Adjusted EPS loss was $3.60, better than expected. Operating margin declined to -45.5% due to R&D expenses. Management highlighted growth in OPZELURA and hematology-oncology brands, with continued investment in pipeline and acquisitions pressuring margins.